secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hoth Therapeutics, Inc. (HOTH)
CIK:        0001711786
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001013762-25-002271
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hoth restates 2023, 2024 financials for prepaid R&D errors; initiates HT-KIT toxicity study
--------------------------------------------------------------------------------

- Restatement: prepaid expenses understated by $722,765 at Dec 31, 2023; R&D expenses understated by $260,732 for FY2023.
- Quarterly restatements for 2023-2024: prepaid assets understated by $442k-$983k; R&D expenses understated by $52k-$280k.
- Enters Project Order with OnTargetx for 4-week IV toxicity study of HT-KIT (mast cell cancer) at cost of $354,219.
- Restatement impacts operating cash flows but total cash unchanged; 2024 10-K to include restated periods.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711786/000101376225002271/0001013762-25-002271-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711786/000101376225002271/ea0235633-8k_hoth.htm
  HTML page:      https://secwatch.observer/filing/0001013762-25-002271

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer